Goldman Sachs resumed coverage of Avidity Biosciences (RNA) with a Buy rating and $55 price target The firm expects clarity over the next 12-18 months on the company’s regulatory outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications
- Lyft upgraded, Block assumed: Wall Street’s top analyst calls
- Avidity Biosciences initiated with an Outperform at Bernstein
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating